Publications | ERC

News Publications

ERC Belgium balance sheet for the financial year ending 31 Dec 2022

Cohort Study of GLIOVAC/ERC1671/SITOIGANAP to treat Glioblastoma

Review - Therapeutic Immunization against Glioblastoma – Virgil Schijns

Phase II study of ERC1671/SITOIGANAP plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.

Therapeutic vaccination against malignant gliomas Q1 based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat

Use of ERC-1671/SITOIGANAP Vaccine in a patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.

Therapeutic vaccination against malignant gliomas Q1 based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat.

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined all- and auto-immune tumor reactivity.

Cancer Immunology.

Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation

Pages